Literature DB >> 25876905

Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Jan Kriz1, Max Spickermann, Philipp Lehrich, Heinz Schmidberger, Gabriele Reinartz, Hans Eich, Uwe Haverkamp.   

Abstract

INTRODUCTION: The present study addresses the role of intensity-modulated radiotherapy (IMRT) in contrast to standard RT (APPA) for patients with Hodgkin's lymphoma (HL) with a focus on deep inspiration breath-hold (DIBH) technique and a comparison between the International Lymphoma Radiation Oncology Group (ILROG) Involved Site Radiotherapy (IS-RT) versus the German Hodgkin Study Group (GHSG) Involved Field Radiotherapy (IF-RT).
METHODS: APPA treatment and 2 IMRT plans were compared for 11 patients with HL. Furthermore, treatment with DIBH versus free breathing (FB) and two different treatment volumes, i.e. IF-RT versus IS-RT, were compared. IMRT was planned as a sliding-window technique with 5 and 7 beam angles. For each patient 12 different treatment plans were calculated (132 plans). Following organs at risk (OAR) were analysed: lung, heart, spinal cord, oesophagus, female breast and skin. Comparisons of the different values with regard to dose-volume histograms (DVH), conformity and homogeneity indices were made.
RESULTS: IS-RT reduces treatment volumes. With respect to the planning target volume (PTV), IMRT achieves better conformity but the same homogeneity. Regarding the D mean for the lung, IMRT shows increased doses, while RT in DIBH reduces doses. The IMRT shows improved values for Dmax concerning the spinal cord, whereas the APPA shows an improved D mean of the lung and the female breast.
CONCLUSION: IS-RT reduces treatment volumes. Intensity-modulated radiotherapy shows advantages in the conformity. Treatment in DIBH also reduces the dose applied to the lungs and the heart.

Entities:  

Mesh:

Year:  2015        PMID: 25876905     DOI: 10.1007/s00066-015-0839-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  30 in total

1.  Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.

Authors:  Julia Koeck; Yasser Abo-Madyan; Frank Lohr; Florian Stieler; Jan Kriz; Rolf-Peter Mueller; Frederik Wenz; Hans Theodor Eich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

Review 2.  Normal tissue tolerance dose metrics for radiation therapy of major organs.

Authors:  Michael T Milano; Louis S Constine; Paul Okunieff
Journal:  Semin Radiat Oncol       Date:  2007-04       Impact factor: 5.934

3.  Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.

Authors:  Damien C Weber; Nicolas Peguret; Giovanna Dipasquale; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-01       Impact factor: 7.038

4.  Distribution of coronary artery stenosis after radiation for breast cancer.

Authors:  Greger Nilsson; Lars Holmberg; Hans Garmo; Olov Duvernoy; Iwar Sjögren; Bo Lagerqvist; Carl Blomqvist
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

5.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

Authors:  Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-06-18       Impact factor: 7.038

6.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

7.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.

Authors:  Bhishamjit S Chera; Christina Rodriguez; Christopher G Morris; Debbie Louis; Daniel Yeung; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-20       Impact factor: 7.038

9.  Optimization by visualization of indices.

Authors:  Uwe Haverkamp; Darius Norkus; Jan Kriz; Mariam Müller Minai; Franz-Josef Prott; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2014-06-28       Impact factor: 3.621

Review 10.  Radiation-related heart disease: current knowledge and future prospects.

Authors:  Sarah C Darby; David J Cutter; Marjan Boerma; Louis S Constine; Luis F Fajardo; Kazunori Kodama; Kiyohiko Mabuchi; Lawrence B Marks; Fred A Mettler; Lori J Pierce; Klaus R Trott; Edward T H Yeh; Roy E Shore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

View more
  13 in total

1.  Reduction of cardiac and coronary artery doses in irradiation of left-sided breast cancer during inspiration breath hold : A planning study.

Authors:  S Schönecker; C Heinz; M Söhn; W Haimerl; S Corradini; M Pazos; C Belka; H Scheithauer
Journal:  Strahlenther Onkol       Date:  2016-09-08       Impact factor: 3.621

2.  [Risk of heart failure in patients with Hodgkin lymphoma after radiation and anthracycline chemotherapy].

Authors:  J Kriz; H T Eich
Journal:  Strahlenther Onkol       Date:  2017-08       Impact factor: 3.621

3.  New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.

Authors:  J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfarth; P Lukas; H Schmidberger; S Marnitz-Schulze; M Fuchs; A Engert; H T Eich
Journal:  Strahlenther Onkol       Date:  2016-09-27       Impact factor: 3.621

4.  Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

Authors:  C Baues; R Semrau; U S Gaipl; P J Bröckelmann; J Rosenbrock; A Engert; S Marnitz
Journal:  Strahlenther Onkol       Date:  2016-10-04       Impact factor: 3.621

5.  Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).

Authors:  J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfart; P Lukas; A Plütschow; H Schmidberger; S Staar; M Fuchs; A Engert; H T Eich
Journal:  Strahlenther Onkol       Date:  2016-09-05       Impact factor: 3.621

6.  Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy.

Authors:  Eva Holzhäuser; Maximilian Berlin; Daniel Wollschläger; Thomas Bezold; Arnulf Mayer; Georg Heß; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2017-07-26       Impact factor: 3.621

Review 7.  Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.

Authors:  Michael J McKay; Kim L Taubman; Szeting Lee; Andrew M Scott
Journal:  Ann Nucl Med       Date:  2022-01-14       Impact factor: 2.668

8.  Cone-beam CT-guided radiotherapy in the management of lung cancer: Diagnostic and therapeutic value.

Authors:  Khaled Elsayad; Jan Kriz; Gabriele Reinartz; Sergiu Scobioala; Iris Ernst; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2015-12-02       Impact factor: 3.621

9.  Study of an Oxygen Supply and Oxygen Saturation Monitoring System for Radiation Therapy Associated with the Active Breathing Coordinator.

Authors:  Guanzhong Gong; Yujie Guo; Xuemei Sun; Xiuying Wang; Yong Yin; David Dagan Feng
Journal:  Sci Rep       Date:  2018-01-19       Impact factor: 4.379

10.  Comparison of virtual non-contrast dual-energy CT and a true non-contrast CT for contouring in radiotherapy of 3D printed lung tumour models in motion: a phantom study.

Authors:  Dominik Alexander Hering; Kai Kröger; Ralf W Bauer; Hans Theodor Eich; Uwe Haverkamp
Journal:  Br J Radiol       Date:  2020-10-01       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.